Colorectal Cancer and KRAS/BRAF

Colorectal Cancer and KRAS/BRAF - Medscape Reference

Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with ...

Concomitant KRAS and BRAF mutations in colorectal cancer - PMC

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAP-kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations ...

Correlation between KRAS, NRAS and BRAF mutations and tumor ...

Frequency of KRAS, NRAS and BRAF mutations in colorectal cancer ... KRAS mutations were detected in 190 (38%) patients, NRAS mutations in 20 (4%) patients, and ...

BRAF and KRAS mutations in metastatic colorectal cancer

In this review, we focus on BRAF and KRAS mutations to understand the mechanisms underlying resistance and improving the response rate, outcomes, and prognosis ...

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers ...

KRAS mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer.

Opposing roles by KRAS and BRAF mutation on immune cell ...

The opposing relationships of BRAF and KRAS mutations with tumour infiltration of cytotoxic T cells was validated in an independent cohort of ...

The current understanding on the impact of KRAS on colorectal cancer

BRAF mutations are identified in around 4% of the mcrosatellite low (MSI-low) and 40% in MSI-high CRC tissues [4]. TP53 mutation accounts for 43% of all the CRC ...

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting ...

KRAS mutation analysis allows additional useful risk stratification, in rectal and, possibly, colon cancer. pMMR patients wild-type for KRAS have an ...

The prognostic significance of KRAS and BRAF mutation status in ...

In this study, BRAF mutations were found in 4.0% of colorectal cancers, which is slightly lower than previous reports worldwide (Table 6) [36,37 ...

KRAS and BRAF Mutations in Stage II and III Colon Cancer

Both KRAS and BRAF mutations were statistically significantly associated with both DFS and OS, with the mutation effect being enhanced by MSI adjustment.

Efficacy of encorafenib and cetuximab therapy in a young patient ...

At present, the mutational status of KRAS, NRAS, and BRAF genes is initially routinely analyzed in patients with metastatic colorectal cancer. The BRAF p.V600E ...

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer ...

We found that cultured human CRC cells harboring KRAS or BRAF mutations are selectively killed when exposed to high levels of vitamin C. This effect is due to ...

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of ...

Background: RAS and BRAF mutations are associated with lack of response to anti-EGFR therapy and worse survival in patients with metastatic colorectal ...

KRAS, NRAS and BRAF Variant Analysis and MicroRNA Expression ...

KRAS variants are found in approximately 30–50% of colorectal cancer tumors and are common in other tumor types. The NRAS gene can harbor ...

RAS and BRAF in metastatic colorectal cancer management - Gong

In a recent pooled analysis, the prevalence of RAS mutations in mCRC has been shown to be as high as 55.9% with mutations in KRAS exon 2 being the most common ( ...

Differences of protein expression profiles, KRAS and BRAF mutation ...

NRAS mutations (codons 12, 13 and 61) were reported to occur in 3–5% of colorectal cancer. NRAS mutation was a predictive factor of response to ...

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as ...

Conclusion. Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 ...

A combined oncogenic pathway signature of BRAF, KRAS and ... - Gut

Three signalling pathway signatures were developed to characterise specific types of oncogenic mutations in colon cancer (KRAS, BRAF or PIK3CA). The results ...

Vitamin C May Have Clinical Benefit Against KRAS- and BRAF ...

About 50% of colorectal cancers (CRC) harbor an activating KRAS or BRAF mutation. In mice, high-dose vitamin C (4 g/kg intraperitoneal ...

Mutation Status and Immunohistochemical Correlation of KRAS ...

The results showed that KRAS/NRAS/BRAF mutation rates in colon cancer were 44.2, 1.2, and 3.5%; in rectal cancer were 37.1, 4.3, and 0.7%; in ...